/stocks — the workspaceLOADING
All BBOT SEC filings, by type → · Earnings date & implied move · Search inside filings
BridgeBio Oncology Therapeutics, Inc. (BBOT) is a pharmaceutical preparations company. 5 insider Form 4 filings in the last 90 days. Fundamentals from SEC filings; prices are end-of-day.
What’s behind BBOT’s latest move — the size, how unusual the volume is, and the catalyst on the tape, explained and cited to the source.
End-of-day bars · delayed, not real-time · data: Databento · studies computed in your browser from these barsCharting by TradingView Lightweight Charts™
XBRL company facts, SEC EDGAR. TTM = last four reported quarters. Valuation ratios arrive with a price source — we don't fake quotes.
Estimates, not targets. The DCF treats free cash flow as cash flow to equity and divides by shares (the common retail shortcut — it skips net debt and a full WACC), so it’s a sanity-check, not a valuation opinion. All inputs are from BBOT’s SEC filings; change any assumption above and the numbers update live. Educational only — not investment advice.
Not reported in XBRL for this filer.
A plain-English read on BBOT plus an auto-SWOT — built from BBOT's SEC filings and market data, every point cited, nothing invented. Educational, not investment advice.
Four AI analysts — a bull, a bear, a risk manager, and a PM — debate BBOT using only the SEC-filing and market facts below. Every point cites its evidence; nothing is invented. This is educational research, not investment advice.
Educational only — not financial advice. Data from SEC EDGAR public filings; no live market data is shown. Figures reflect the company's own reported XBRL facts and may lag.
Has BBOT been issuing shares? Offering history →
↓ Download the fiscal-year statement table (XLSX) · revenue, income, EPS, cash flow, balance sheet · from SEC XBRL, dated
No lawmaker has disclosed a trade in BBOT under the STOCK Act.
Total return including reinvested dividends, from BBOT’s adjusted closing prices. Past return is not a forecast and not investment advice.
Projected from BBOT's own SEC 8-K filing history — the year-over-year reporting pattern (about 47% land the exact day, about 91% within a week, measured across 4,713 past reports). No analyst estimates and nothing invented, and every confirmed date links to the source it came from, so you can check it yourself. It upgrades the momentBBOT files or announces.
BBOT has rallied after 3 of its last 4 earnings reports.
Each figure is one earnings reaction — how much BBOT moved from the closing price the day before a report to the close the day after. Based on its last 4 reports.
Earnings reactions have been mild.
BBOT has traded higher after most recent earnings releases.
A more typical earnings reaction has been approximately ±2.4%.
Realized close-to-close history only — no options-implied move, no analyst estimates.
| Reported | Close-to-close |
|---|---|
| 2026-08-11 | +1.5% |
| 2026-05-12 | +2.4% |
| 2026-03-05 | +2.5% |
| 2025-11-12 | -2.9% |
Earnings dates are the company's 8-K Item 2.02 filings (SEC). Reactions from Databento EOD.
No tracked institution reported a position in BBOT in the latest 13F round.
Every registered fund files its complete portfolio with the SEC. These weights come from those filings, so each one carries the period it describes. Holdings are quarterly and filed in arrears — the figures below are as of 2026-06-30, not today.
| Fund | Weight | As of |
|---|---|---|
| VTI Vanguard Total Stock Market ETF | <0.01% | 2026-06-30 |
Drawn from 39 large US equity funds we scan, not every fund in existence, so a missing fund means we do not scan it rather than that it holds none. Holdings are joined to tickers by issuer name, which does not resolve every position; what that misses is published.
Head office: South San Francisco, California, United States · the company’s charter and its head office are in different states.
Source: the cover page of BridgeBio Oncology Therapeutics, Inc.’s 10-Q filed 2026-08-11, on EDGAR. Filings checked 2026-10-15. Incorporation is where the company’s charter was filed. It is not where the business operates or earns, which no filing cover states. How this works
No open-market Form 4 buys or sells reported for BBOT in the last ~6 months.